Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Winton · SciRah

Researcher profile · Semantic Scholar

E. Winton

Share profile

E. Winton — researcher profile on SciRah

h-index: 37
Works: 172
Citations: 8,222

Most-cited papers

A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +20 more
2012New England Journal of Medicine1,948 citations Open access
Semantic Scholar
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
S. Verstovsek, R. Mesa, J. Gotlib, V. Gupta +17 more
2017Journal of Hematology & Oncology410 citations Open access
Semantic Scholar
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
R. Mesa, J. Kiladjian, J. Catalano, T. Devos +10 more
2017Journal of Clinical Oncology330 citations Open access
Semantic Scholar
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +18 more
2013Haematologica323 citations Open access
Semantic Scholar
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
C. Harrison, N. Schaap, A. Vannucchi, J. Kiladjian +12 more
2017The Lancet Haematology307 citations Open access
Semantic Scholar
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
C. Harrison, A. Vannucchi, U. Platzbecker, F. Cervantes +9 more
2018The Lancet Haematology286 citations
Semantic Scholar
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
R. Mesa, J. Gotlib, V. Gupta, J. Catalano +14 more
2013Journal of Clinical Oncology180 citations Open access
Semantic Scholar
Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea.
A. Yacoub, J. Mascarenhas, H. Kosiorek, J. Prchal +30 more
2019Blood166 citations Open access
Semantic Scholar
Acquired Copper Deficiency: A Potentially Serious and Preventable Complication Following Gastric Bypass Surgery
D. Griffith, D. Liff, Thomas R. Ziegler, Gregory J. Esper +1 more
2009Obesity154 citations Open access
Semantic Scholar
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi +39 more
2022Blood129 citations Open access
Semantic Scholar
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
D. DeAngelo, D. Radia, T. George, W. Robinson +14 more
2021Nature Medicine127 citations Open access
Semantic Scholar
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +19 more
2013Haematologica124 citations Open access
Semantic Scholar
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas, M. Talpaz, V. Gupta, Lynda M. Foltz +12 more
2017Haematologica102 citations Open access
Semantic Scholar
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
M. Talpaz, R. Paquette, L. Afrin, S. Hamburg +18 more
2013Journal of Hematology & Oncology95 citations Open access
Semantic Scholar
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +19 more
2013British Journal of Haematology91 citations Open access
Semantic Scholar
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters
Ha Tran, M. Arellano, A. Chamsuddin, C. Flowers +7 more
2010Leukemia and Lymphoma88 citations
Semantic Scholar
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Kim-Hien T. Dao, J. Gotlib, Michael W. Deininger, Stephen T. Oh +22 more
2019Journal of Clinical Oncology87 citations Open access
Semantic Scholar
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
S. Parikh, H. Kantarjian, A. Schimmer, W. Walsh +4 more
2010Clinical Lymphoma, Myeloma & Leukemia83 citations
Semantic Scholar
Ruxolitinib - a Steroid Sparing Agent in Chronic Graft-versus-Host Disease
H. Khoury, A. Langston, V. Kota, J. Wilkinson +10 more
2018Bone Marrow Transplantation76 citations Open access
Semantic Scholar
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
Kim-Hien T. Dao, M. Solti, Julia E. Maxson, E. Winton +3 more
2014Leukemia Research Reports76 citations Open access
Semantic Scholar
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
R. Mesa, J. Kiladjian, S. Verstovsek, H. Al-Ali +31 more
2014Haematologica47 citations Open access
Semantic Scholar
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia
M. Arellano, S. Pakkala, A. Langston, M. Tighiouart +6 more
2012Cancer47 citations
Semantic Scholar
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi +31 more
2018Blood44 citations
Semantic Scholar
Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +15 more
2011Journal of Clinical Oncology43 citations
Semantic Scholar
Characteristics and outcomes of diffuse large B‐cell lymphoma presenting in leukaemic phase
Disni Muringampurath-John, David L. Jaye, Christopher R. Flowers, D. Saxe +13 more
2012British Journal of Haematology37 citations
Semantic Scholar
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second‐line agents, and beyond
L. Lima, L. Bernal-Mizrachi, D. Saxe, K. Mann +7 more
2011Cancer37 citations Open access
Semantic Scholar
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
J. Mascarenhas, J. Prchal, A. Rambaldi, R. Mesa +33 more
201636 citations
Semantic Scholar
Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +19 more
201235 citations
Semantic Scholar
Spectrum of FDG PET/CT Findings in Burkitt Lymphoma
Wan-Zhen Zeng, M. Lechowicz, E. Winton, S. Cho +2 more
2009Clinical Nuclear Medicine35 citations
Semantic Scholar
A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
J. Lancet, V. Duong, E. Winton, R. Stuart +7 more
2011Clinical Cancer Research34 citations Open access
Semantic Scholar
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies
Ana G. Antun, S. Gleason, M. Arellano, A. Langston +8 more
2013Cancer33 citations Open access
Semantic Scholar
Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +19 more
201331 citations
Semantic Scholar
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy +19 more
201130 citations
Semantic Scholar
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma
Z. Mitri, M. Siddiqui, F. El Rassi, J. Holden +9 more
2014Leukemia and Lymphoma25 citations
Semantic Scholar
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub +28 more
2019Leukemia24 citations Open access
Semantic Scholar
Autoimmune autonomic ganglionopathy treated with long-term rituximab in a patient with lymphoma
Ryan D. Hollenbeck, Bonnie K. Black, Amanda Peltier, I. Biaggioni +3 more
2010Archives of Neurology24 citations Open access
Semantic Scholar
Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?
F. El Rassi, John D. Bergsagel, M. Arellano, M. Gaddh +5 more
2015Cancer23 citations Open access
Semantic Scholar
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
A. Jillella, M. Arellano, M. Gaddh, A. Langston +19 more
2020JCO Oncology Practice22 citations Open access
Semantic Scholar
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
R. Mesa, H. Kosiorek, J. Mascarenhas, J. Prchal +29 more
2016Blood18 citations Open access
Semantic Scholar
Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)
C. Harrison, N. Schaap, S. Zweegman, E. Jourdan +19 more
201318 citations
Semantic Scholar
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma
S. Murali, E. Winton, E. Waller, L. T. Heffner +8 more
2008Bone Marrow Transplantation18 citations Open access
Semantic Scholar
Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
C. Harrison, A. Vannucchi, U. Platzbecker, F. Cervantes +9 more
201717 citations
Semantic Scholar
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera
Alexander Coltoff, R. Mesa, J. Gotlib, J. Shulman +14 more
2020Clinical Lymphoma, Myeloma & Leukemia16 citations Open access
Semantic Scholar
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
E. Winton, V. Kota
2017Future Oncology15 citations
Semantic Scholar
Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts
M. Talpaz, R. Paquette, L. Afrin, S. Hamburg +16 more
201215 citations
Semantic Scholar
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Abdulraheem Yacoub, U. Borate, R. Rampal, H. Ali +17 more
2024Blood Advances14 citations Open access
Semantic Scholar
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
J. Kong, E. Winton, L. Heffner, Zheng-Jia Chen +9 more
2017Cancer14 citations Open access
Semantic Scholar
High‐dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years
M. Arellano, E. Winton, L. Pan, L. Lima +8 more
2012Cancer14 citations
Semantic Scholar
Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
H. J. Khoury, V. Kota, M. Arellano, Stephanie L. Bauer +7 more
201513 citations Open access
Semantic Scholar
Managing chronic myeloid leukemia: a coordinated team care perspective.
Stacie Holloway, Katharine Lord, Beverly Bethelmie-Bryan, Marian Shepard +13 more
2012Clinical Lymphoma, Myeloma & Leukemia13 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Mesa×20
Invite
R. Mesa — researcher profile on SciRah
S. Verstovsek×18
Invite
S. Verstovsek — researcher profile on SciRah
R. Silver×18
Invite
R. Silver — researcher profile on SciRah
M. Talpaz×16
Invite
M. Talpaz — researcher profile on SciRah

×15

Invite

J. Gotlib — researcher profile on SciRah

Invite

M. Arcasoy — researcher profile on SciRah

Invite

V. Gupta — researcher profile on SciRah

H. Kantarjian×14

Invite

H. Kantarjian — researcher profile on SciRah

M. Arellano×14

Invite

M. Arellano — researcher profile on SciRah

Invite

R. Levy — researcher profile on SciRah

M. Deininger×12

Invite

M. Deininger — researcher profile on SciRah

Invite

E. Hexner — researcher profile on SciRah